Allergan’s patent deal with the Saint Regis Mohawk Tribe, in an attempt to protect itself from an inter partes review on Restasis, drew a huge number of headlines, mostly condemnatory; now, the judgement as to whether this manoeuvre is valid has come back, and it isn’t positive for Allergan.
The US’ Patent Trial and Appeal Board (PTAB) rejected the Native American’s move to block Mylan’s patent challenge thereby nulling Allergan’s attempts to avoid a patent challenge from this angle.
